mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 9, Pages e104413
Publisher
Public Library of Science (PLoS)
Online
2014-09-03
DOI
10.1371/journal.pone.0104413
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo
- (2013) J. Renshaw et al. CLINICAL CANCER RESEARCH
- Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
- (2013) Karen E. Sheppard et al. EUROPEAN JOURNAL OF CANCER
- mTOR kinase structure, mechanism and regulation
- (2013) Haijuan Yang et al. NATURE
- Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells
- (2013) Heloisa P. Soares et al. PLoS One
- Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models
- (2013) Hua Zhong et al. PLoS One
- TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma
- (2013) R. B. Corcoran et al. Science Translational Medicine
- Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma
- (2013) Alessandro Conti et al. Biomed Research International
- The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
- (2012) E J Haagensen et al. BRITISH JOURNAL OF CANCER
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
- (2012) G. Migliardi et al. CLINICAL CANCER RESEARCH
- Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
- (2012) P. J. Roberts et al. CLINICAL CANCER RESEARCH
- The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance
- (2012) Bao Hoang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy
- (2011) Cheng-Xiong Xu et al. CANCER BIOLOGY & THERAPY
- In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
- (2011) K. M. Kinross et al. MOLECULAR CANCER THERAPEUTICS
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- Genetic and Functional Studies Implicate HIF1 as a 14q Kidney Cancer Suppressor Gene
- (2011) C. Shen et al. Cancer Discovery
- Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy
- (2010) Xuerong Wang et al. CANCER BIOLOGY & THERAPY
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
- (2009) K. Yu et al. CANCER RESEARCH
- The Pharmacology of mTOR Inhibition
- (2009) D. A. Guertin et al. Science Signaling
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- mTOR pathway in renal cell carcinoma
- (2008) Sara C Hanna et al. Expert Review of Anticancer Therapy
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search